Labsystems Diagnostics, Helsinki, an enterprise of Trivitron Healthcare, the fast growing healthcare multinational headquartered in Chennai, has entered into a pact with Shimadzu Corporation, Japan, leader in analytical instruments, for clinical diagnostics in the area of Newborn Screening (NBS).
Now NBS is a preventive paediatric screening service to assess the occurrence of genetic metabolic disorders. These disorders could lead to permanent neurological, cognitive, and physical damage in the child. When these disorders are detected early enough they can be easily treated.
The companies will cooperate to leverage Labsystems reagent technology leadership and Shimadzu world class instrumentation to enable their global customer base to detect more disorders in newborns, more rapidly and with greater accuracy.
The association ensures access to the new generation NeoMass AAAC assay fully validated on Shimadzu mass spectrometry platforms. NeoMass AACC enables investigators for the first time to detect the entire spectrum of Urea Cycle Metabolic Disorders (UCMD) in newborns. This assay detects the broadest range of non derivatized analytes.
Fabrizio RADICE, global sales & marketing director, Labsystems Diagnostics, Helsinki stated that development of NeoMass AACC is only the start. Co-development will allow us to leverage the technology leadership of Shimadzu instrumentation to provide sensitivity to new disorders, and to provide faster throughput and greater accuracy, which is the key to investigators success in detecting disorders in babies.
“We believe our cooperation will have an impact on the suffering caused by these severe, yet eminently preventable diseases”, he added.
According to Dr. Geraldine Carrard, CEO, Labsystems Diagnostics Oy, the deliberations and discussions have paved the way of a trusted and solid partnership. Shimadzu Trivitron Labsystems Diagnostics combination will be an innovative driving force to reckon within the Newborn Screening.”
Shuzo Maruyama, General Manager, Analytical & Measuring Instruments Division, Shimadzu Corporation said that the agreement will help to change the way in new born screening programs can be better, expanding the screening capability with detailed analytics and actionable data creating a new solution for faster, confident diagnosis. Shimadzu is always exploring ways to find a solution that meets a real need and makes a difference to overcome real world challenges.
“Two world leaders Shimadzu and Labsystems will create a winning combination improving access and affordability for newborn screening solutions across the globe”, said Dr. G.S.K. Velu, chairman & managing director, Trivitron Group of Companies.